248 related articles for article (PubMed ID: 28692178)
21. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study.
Biancon G; Gimondi S; Vendramin A; Carniti C; Corradini P
J Mol Diagn; 2018 Nov; 20(6):859-870. PubMed ID: 30165206
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.
Caivano A; La Rocca F; Simeon V; Girasole M; Dinarelli S; Laurenzana I; De Stradis A; De Luca L; Trino S; Traficante A; D'Arena G; Mansueto G; Villani O; Pietrantuono G; Laurenti L; Del Vecchio L; Musto P
Cell Oncol (Dordr); 2017 Feb; 40(1):97-103. PubMed ID: 27761889
[TBL] [Abstract][Full Text] [Related]
23. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
24. [DNA diagnosis in hematological malignancies].
Nara N
Rinsho Byori; 2001 Mar; Suppl 115():37-44. PubMed ID: 11391935
[TBL] [Abstract][Full Text] [Related]
25. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
[TBL] [Abstract][Full Text] [Related]
26. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
27. Biological implications of clonal hematopoiesis.
Luis TC; Wilkinson AC; Beerman I; Jaiswal S; Shlush LI
Exp Hematol; 2019 Sep; 77():1-5. PubMed ID: 31472170
[TBL] [Abstract][Full Text] [Related]
28. The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.
Shi M; Dong X; Huo L; Wei X; Wang F; Sun K
Adv Exp Med Biol; 2018; 1068():119-133. PubMed ID: 29943300
[TBL] [Abstract][Full Text] [Related]
29. [Necessity of Genetic Examination in Treatment for Hematological Malignancies].
Kiyoi H
Rinsho Byori; 2015 Mar; 63(3):369-76. PubMed ID: 26524860
[TBL] [Abstract][Full Text] [Related]
30. [Introduction to the molecular diagnostic methods of oncohematology].
Király AP; Alpár D; Fésüs V; Marosvári D; Matolcsy A; Bödör C
Magy Onkol; 2016 Jun; 60(2):88-98. PubMed ID: 27275635
[TBL] [Abstract][Full Text] [Related]
31. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
Polivka J; Pesta M; Janku F
Expert Rev Mol Diagn; 2015; 15(12):1631-44. PubMed ID: 26559503
[TBL] [Abstract][Full Text] [Related]
32. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.
Bench AJ; Erber WN; Scott MA
Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
35. Implication of cytogenetic and molecular cytogenetic analysis in diagnosis of hematological malignancies in the era of the new sequencing techniques.
Zemanová Z; Michalová K; Březinová J
Cas Lek Cesk; 2019; 158(1):22-27. PubMed ID: 31046388
[TBL] [Abstract][Full Text] [Related]
36. [Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
Nosaka K; Kawaguchi T
Nihon Rinsho; 2012 May; 70(5):835-9. PubMed ID: 22620009
[TBL] [Abstract][Full Text] [Related]
37. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
[TBL] [Abstract][Full Text] [Related]
38. [Free circulating DNA as a tool for lung cancer patients management].
Tissot C; Villar S; Olivier M; Couraud S
Rev Pneumol Clin; 2016 Feb; 72(1):61-71. PubMed ID: 26190335
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease testing in hematologic malignancies and solid cancer.
Ben Lassoued A; Nivaggioni V; Gabert J
Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
[TBL] [Abstract][Full Text] [Related]
40. Novel precision medicine approaches and treatment strategies in hematological malignancies.
Rosenquist R; Bernard E; Erkers T; Scott DW; Itzykson R; Rousselot P; Soulier J; Hutchings M; Östling P; Cavelier L; Fioretos T; Smedby KE
J Intern Med; 2023 Oct; 294(4):413-436. PubMed ID: 37424223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
